Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.

Foo CS, Lupien A, Kienle M, Vocat A, Benjak A, Sommer R, Lamprecht DA, Steyn AJC, Pethe K, Piton J, Altmann KH, Cole ST.

MBio. 2018 Oct 9;9(5). pii: e01276-18. doi: 10.1128/mBio.01276-18.

2.

Identification of 4-Amino-Thieno[2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis.

Harrison GA, Mayer Bridwell AE, Singh M, Jayaraman K, Weiss LA, Kinsella RL, Aneke JS, Flentie K, Schene ME, Gaggioli M, Solomon SD, Wildman SA, Meyers MJ, Stallings CL.

mSphere. 2019 Sep 11;4(5). pii: e00606-19. doi: 10.1128/mSphere.00606-19.

3.

Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection.

Kalia NP, Hasenoehrl EJ, Ab Rahman NB, Koh VH, Ang MLT, Sajorda DR, Hards K, Grüber G, Alonso S, Cook GM, Berney M, Pethe K.

Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):7426-7431. doi: 10.1073/pnas.1706139114. Epub 2017 Jun 26.

4.

Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.

Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O'Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchettini J, Masquelin T, Hipskind PA, Odingo J, Parish T.

ACS Infect Dis. 2017 Dec 8;3(12):898-916. doi: 10.1021/acsinfecdis.7b00112. Epub 2017 Oct 31.

5.

Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.

van der Westhuyzen R, Winks S, Wilson CR, Boyle GA, Gessner RK, Soares de Melo C, Taylor D, de Kock C, Njoroge M, Brunschwig C, Lawrence N, Rao SP, Sirgel F, van Helden P, Seldon R, Moosa A, Warner DF, Arista L, Manjunatha UH, Smith PW, Street LJ, Chibale K.

J Med Chem. 2015 Dec 10;58(23):9371-81. doi: 10.1021/acs.jmedchem.5b01542. Epub 2015 Nov 20.

PMID:
26551248
6.

Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB.

Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernández R, Alemparte C, Remuiñán MJ, Barros D, Ballell L, Besra GS.

PLoS One. 2012;7(12):e52951. doi: 10.1371/journal.pone.0052951. Epub 2012 Dec 31.

7.

Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c.

Moosa A, Lamprecht DA, Arora K, Barry CE 3rd, Boshoff HIM, Ioerger TR, Steyn AJC, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01338-17. doi: 10.1128/AAC.01338-17. Print 2017 Oct.

8.

Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.

Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LA, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2014 Nov;58(11):6962-5. doi: 10.1128/AAC.03486-14. Epub 2014 Aug 25. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

9.

Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.

O'Malley T, Alling T, Early JV, Wescott HA, Kumar A, Moraski GC, Miller MJ, Masquelin T, Hipskind PA, Parish T.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02439-17. doi: 10.1128/AAC.02439-17. Print 2018 Jun.

10.

Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB.

Moraski GC, Seeger N, Miller PA, Oliver AG, Boshoff HI, Cho S, Mulugeta S, Anderson JR, Franzblau SG, Miller MJ.

ACS Infect Dis. 2016 Jun 10;2(6):393-8. doi: 10.1021/acsinfecdis.5b00154. Epub 2016 Apr 12.

PMID:
27627627
11.

Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.

Liu Y, Zhou S, Deng Q, Li X, Meng J, Guan Y, Li C, Xiao C.

Tuberculosis (Edinb). 2016 Mar;97:38-46. doi: 10.1016/j.tube.2015.12.003. Epub 2016 Jan 6.

PMID:
26980494
12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
13.

Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.

Lu X, Williams Z, Hards K, Tang J, Cheung CY, Aung HL, Wang B, Liu Z, Hu X, Lenaerts A, Woolhiser L, Hastings C, Zhang X, Wang Z, Rhee K, Ding K, Zhang T, Cook GM.

ACS Infect Dis. 2019 Feb 8;5(2):239-249. doi: 10.1021/acsinfecdis.8b00225. Epub 2018 Dec 11.

PMID:
30485737
14.

[Prospects for development of new antituberculous drugs].

Tomioka H.

Kekkaku. 2002 Aug;77(8):573-84. Japanese.

PMID:
12235850
15.

Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing.

Subtil FT, Villela AD, Abbadi BL, Rodrigues-Junior VS, Bizarro CV, Timmers LFSM, de Souza ON, Pissinate K, Machado P, López-Gavín A, Tudó G, González-Martín J, Basso LA, Santos DS.

Int J Antimicrob Agents. 2018 Mar;51(3):378-384. doi: 10.1016/j.ijantimicag.2017.08.023. Epub 2017 Aug 23.

16.

Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis.

Berube BJ, Parish T.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01677-17. doi: 10.1128/AAC.01677-17. Print 2018 Jan.

17.

Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.

Vilchèze C, Baughn AD, Tufariello J, Leung LW, Kuo M, Basler CF, Alland D, Sacchettini JC, Freundlich JS, Jacobs WR Jr.

Antimicrob Agents Chemother. 2011 Aug;55(8):3889-98. doi: 10.1128/AAC.00266-11. Epub 2011 May 31.

18.

A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline.

Berney M, Hartman TE, Jacobs WR Jr.

MBio. 2014 Jul 15;5(4):e01275-14. doi: 10.1128/mBio.01275-14.

19.

In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

Villar R, Vicente E, Solano B, Pérez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.

J Antimicrob Chemother. 2008 Sep;62(3):547-54. doi: 10.1093/jac/dkn214. Epub 2008 May 23.

20.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602

Supplemental Content

Support Center